MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4244/eij-d-17-00279

Медицинская библиотека · EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2017

COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction.

Noc Marko, Erlinge David, Neskovic Aleksandar N, Kafedzic Srdjan, Merkely Béla, Zima Endre, Fister Misa, Petrović Milovan, Čanković Milenko, Veress Gábor, Laanmets Peep, Pern Teele, Vukcevic Vladan, Dedovic Vladimir, Średniawa Beata, Świątkowski Andrzej, Keeble Thomas R, Davies John R, Warenits Alexandra-Maria, Olivecrona Göran, Peruga Jan Zbigniew, Ciszewski Michal, Horvath Ivan, Edes Istvan, Nagy Gergely Gyorgy, Aradi Daniel, Holzer Michael

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

AIMS: We aimed to investigate the rapid induction of therapeutic hypothermia using the ZOLL Proteus Intravascular Temperature Management System in patients with anterior ST-elevation myocardial infarction (STEMI) without cardiac arrest.

METHODS AND

RESULTS

A total of 50 patients were randomised; 22 patients (88%; 95% confidence interval [CI]: 69-97%) in the hypothermia group and 23 patients (92%; 95% CI: 74-99) in the control group completed cardiac magnetic resonance imaging at four to six days and 30-day follow-up. Intravascular temperature at coronary guidewire crossing after 20.5 minutes of endovascular cooling decreased to 33.6°C (range 31.9-35.5°C). There was a 17-minute (95% CI: 4.6-29.8 min) cooling-related delay to reperfusion. In "per protocol" analysis, median infarct size/left ventricular mass was 16.7% in the hypothermia group versus 23.8% in the control group (absolute reduction 7.1%, relative reduction 30%; p=0.31) and median left ventricular ejection fraction (LVEF) was 42% in the hypothermia group and 40% in the control group (absolute reduction 2.4%, relative reduction 6%; p=0.36). Except for self-terminating paroxysmal atrial fibrillation (32% versus 8%; p=0.074), there was no excess of adverse events in the hypothermia group.

CONCLUSIONS

We rapidly and safely cooled patients with anterior STEMI to 33.6°C at the time of coronary guidewire crossing. This is ≥1.1°C lower than in previous cooling studies. Except for self-terminating atrial fibrillation, there was no excess of adverse events and no clinically important cooling-related delay to reperfusion. A statistically non-significant numerical 7.1% absolute and 30% relative reduction in infarct size warrants a pivotal trial powered for efficacy.

Для цитирования: Noc Marko, Erlinge David, Neskovic Aleksandar N, Kafedzic Srdjan, Merkely Béla, Zima Endre, Fister Misa, Petrović Milovan, Čanković Milenko, Veress Gábor, Laanmets Peep, Pern Teele, Vukcevic Vladan, Dedovic Vladimir, Średniawa Beata, Świątkowski Andrzej, Keeble Thomas R, Davies John R, Warenits Alexandra-Maria, Olivecrona Göran, Peruga Jan Zbigniew, Ciszewski Michal, Horvath Ivan, Edes Istvan, Nagy Gergely Gyorgy, Aradi Daniel, Holzer Michael. COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2017. DOI: 10.4244/eij-d-17-00279.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.